Biomerica Statistics
Total Valuation
Biomerica has a market cap or net worth of $8.63 million. The enterprise value is $9.70 million.
| Market Cap | 8.63M |
| Enterprise Value | 9.70M |
Important Dates
The next estimated earnings date is Tuesday, October 20, 2026, after market close.
| Earnings Date | Oct 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biomerica has 4.59 million shares outstanding. The number of shares has increased by 26.90% in one year.
| Current Share Class | 4.59M |
| Shares Outstanding | 4.59M |
| Shares Change (YoY) | +26.90% |
| Shares Change (QoQ) | +3.10% |
| Owned by Insiders (%) | 8.92% |
| Owned by Institutions (%) | 12.75% |
| Float | 4.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.97 |
| Forward PS | n/a |
| PB Ratio | 2.32 |
| P/TBV Ratio | 3.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.91.
| Current Ratio | 1.62 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.91 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -112.10% and return on invested capital (ROIC) is -69.44%.
| Return on Equity (ROE) | -112.10% |
| Return on Assets (ROA) | -52.35% |
| Return on Invested Capital (ROIC) | -69.44% |
| Return on Capital Employed (ROCE) | -124.36% |
| Weighted Average Cost of Capital (WACC) | 4.99% |
| Revenue Per Employee | $89,060 |
| Profits Per Employee | -$75,500 |
| Employee Count | 50 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 2.56 |
Taxes
In the past 12 months, Biomerica has paid $23,000 in taxes.
| Income Tax | 23,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.23% in the last 52 weeks. The beta is 0.38, so Biomerica's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -32.23% |
| 50-Day Moving Average | 2.00 |
| 200-Day Moving Average | 2.12 |
| Relative Strength Index (RSI) | 39.00 |
| Average Volume (20 Days) | 25,497 |
Short Selling Information
The latest short interest is 37,158, so 0.81% of the outstanding shares have been sold short.
| Short Interest | 37,158 |
| Short Previous Month | 57,854 |
| Short % of Shares Out | 0.81% |
| Short % of Float | 0.89% |
| Short Ratio (days to cover) | 0.20 |
Income Statement
In the last 12 months, Biomerica had revenue of $4.45 million and -$3.78 million in losses. Loss per share was -$1.30.
| Revenue | 4.45M |
| Gross Profit | 362,000 |
| Operating Income | -5.32M |
| Pretax Income | -3.75M |
| Net Income | -3.78M |
| EBITDA | -5.24M |
| EBIT | -5.32M |
| Loss Per Share | -$1.30 |
Balance Sheet
The company has $1.31 million in cash and $2.38 million in debt, with a net cash position of -$1.08 million or -$0.23 per share.
| Cash & Cash Equivalents | 1.31M |
| Total Debt | 2.38M |
| Net Cash | -1.08M |
| Net Cash Per Share | -$0.23 |
| Equity (Book Value) | 2.63M |
| Book Value Per Share | 0.82 |
| Working Capital | 1.54M |
Cash Flow
| Operating Cash Flow | -3.42M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 77,000 |
| Net Borrowing | 500,000 |
| Free Cash Flow | -3.42M |
| FCF Per Share | -$0.75 |
Margins
Gross margin is 8.13%, with operating and profit margins of -119.47% and -84.77%.
| Gross Margin | 8.13% |
| Operating Margin | -119.47% |
| Pretax Margin | -84.26% |
| Profit Margin | -84.77% |
| EBITDA Margin | -117.74% |
| EBIT Margin | -119.47% |
| FCF Margin | n/a |
Dividends & Yields
Biomerica does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.90% |
| Shareholder Yield | -26.90% |
| Earnings Yield | -43.07% |
| FCF Yield | -39.03% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 21, 2025. It was a reverse split with a ratio of 1:8.
| Last Split Date | Apr 21, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Biomerica has an Altman Z-Score of -12.36 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.36 |
| Piotroski F-Score | 2 |